Researchers at nference found pain was the top reason for use and about a third got it from gray-market vendors, while outside experts say benefits remain unproven.
Recap by typeshit. Full story at The American Journal of Managed Care.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Strong sales of its obesity injections pushed Lilly past profit expectations, and the drugmaker raised its full-year outlook, Reuters reports.
Ricks describes working with the Trump administration to lower obesity drug costs for older Americans, on the day Lilly posted third-quarter earnings.
Loading…